7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy

Patent metadata

Field	Value
Publication number	US-11147776-B2
Application number	US-201916591702-A
Country	US
Kind code	B2
Filing date	Oct 3, 2019
Priority date	Jun 27, 2014
Publication date	Oct 19, 2021
Grant date	Oct 19, 2021

Abstract

The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.

First claim

The invention claimed is:

1. A method of treating tonic-clonic seizures in a subject with epilepsy comprising administering a therapeutically effective amount of 7-hydroxy-cannabidiol (7-OH-CBD), thereby treating tonic-clonic seizures.

2. The method of claim 1 , wherein the 7-OH-CBD is in a pure, isolated or synthetic form.

3. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of 7-hydroxy-cannabidivarin (7-OH-CBDV).

4. The method of claim 1 , wherein the 7-OH-CBD is administered as a pharmaceutical composition comprising the 7-OH-CBD with a pharmaceutically acceptable carrier.

5. The method of claim 1 , further comprising administering to the subject one or more concomitant anti-epileptic drugs (AED).

6. The method of claim 5 , wherein the one or more AED is selected from the group consisting of: clobazam; levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin.

7. The method of claim 1 , wherein the dose of 7-OH-CBD is between 1 and 2000 mg/kg.

8. The method of claim 3 , wherein the 7-OH-CBD is formulated for administration separately, sequentially or simultaneously with the 7-OH-CBDV or the combination is provided in a single dosage form.

9. The method of claim 3 , wherein the 7-OH-CBDV is in a pure, isolated or synthetic form.

10. The method of claim 3 , wherein the dose of 7-OH-CBDV is between 1 and 2000 mg/kg.

11. The method of claim 4 , wherein the pharmaceutical composition further comprises 7-hydroxy-cannabidivarin (7-OH-CBDV).

12. A pharmaceutical composition comprising 7-hydroxy-cannabidiol (7-OH-CBD) with a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition further comprises 7-hydroxy-cannabidivarin (7-OH-CBDV).

14. The pharmaceutical composition of claim 12 , wherein the 7-OH-CBD is in a pure, isolated or synthetic form.

15. The pharmaceutical composition of claim 12 , wherein the composition is formulated to have a dose of 7-OH-CBD between 1 and 2000 mg/kg.

16. The pharmaceutical composition of claim 13 , wherein the 7-OH-CBD is formulated for administration separately, sequentially or simultaneously with the 7-OH-CBDV.

17. The pharmaceutical composition of claim 13 , wherein the 7-OH-CBD and 7-OH-CBDV are provided in a single dosage form.

18. The method of claim 1 , wherein the 7-OH-CBD is administered in an oral solution comprising the 7-OH-CBD and a pharmaceutically acceptable carrier.

19. The method of claim 1 , wherein the administering treats myoclonic jerks.

20. The method of claim 1 , wherein the administering reduces seizure severity.

21. The method of claim 1 , wherein the administering reduces latency to seizure onset.

Assignees

• Gw Res Ltd

Inventors

• Stott Colin
• Jones Nick
• Whalley Benjamin
• Stephens Gary
• Williams Claire

Classifications

• A61K36/3482

  Cannabis · CPC title

• A61K31/658 Primary

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title